Barclays CEO Undergoing Treatment for Non-Hodgkin Lymphoma

Barclays PLC and Barclays Bank PLC (“Barclays”) announces that its CEO, C.S. Venkatakrishnan, has informed the Barclays Board and his colleagues that he will be undergoing treatment for Non-Hodgkin Lymphoma.  His letter on this subject is below:

“Dear Colleagues:

I am writing to inform you that I have been diagnosed with Non-Hodgkin Lymphoma.  The good news is that the matter has been detected early, with scans and biopsies confirming it to be very localised.

My treatment is at Memorial Sloan Kettering Cancer Center in New York.   The doctors have advised that my prognosis is excellent, and my condition is curable with their prescribed regimen.  This is likely to last 12 to 16 weeks.  During this period, the company will run normally, and I will continue to be actively engaged in managing it.  However, I will have to work from home for some periods and not be able to travel. Fortunately, I have always exercised regularly and am strong and fit as I commence this treatment.

The Board has been kept apprised of my situation and I am enormously grateful for their support.

We have a highly capable and seasoned Executive Committee, supported by a talented senior management team.  I am very confident that we will continue, with your help, to serve our customers and clients well, and produce strong operating performance for our shareholders.

I am deeply appreciative, and very proud, of your support and extraordinary efforts in these volatile times.”

Source: Barclays